Value
4.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 4.0 |
ERAS · Why this verdict
Why Erasca (ERAS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.4/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
With 26.6% headroom to the analyst price target at a roughly 3.8-to-1 favorable risk/reward ratio and institutions accumulating the stock, the setup offers meaningful upside for a speculative position if the clinical pipeline advances. Sentiment breakdown | Price converges toward the $18.27 analyst target over 12 months driven by positive clinical data from one or both programs. | →Stable |
| CounterAnalyst coverage is light, which dampens signal reliability; if the latest large earnings miss reflects a change in the development trajectory, the target may be revised downward before price has a chance to reach it. | ||
The business is burning cash with no revenue-generating operations, negative free cash flow, and no established competitive moat, leaving the quality profile well below the minimum threshold for a position addition at a score of roughly 1.6 out of 10. Quality breakdown | Operating free cash flow turns positive for 2 consecutive quarters as the company moves toward a more capital-efficient clinical model. | →Stable |
| CounterEarly-stage biotechnology companies by definition burn cash ahead of clinical milestones; the low financial-quality score reflects the stage of development rather than permanent impairment, and a positive clinical read-out from either program could transform the profile rapidly. | ||
The company's entire value rests on two Phase 1 clinical programs — ERAS-0015 and ERAS-4001 — leaving the investment exposed to binary read-out risk with no diversification from commercial products or late-stage assets. Bear case | At least one of the two Phase 1 programs advances to Phase 2 within 18 months, validating the clinical development path. | →Stable |
| CounterPipeline concentration is inherent to early-stage biotech; the 26.6% analyst-target upside suggests the market is already pricing in clinical risk, and institutional accumulation signals confidence in the probability of advancement. | ||
The stock is in a confirmed breakout — golden cross in place, trading above all major moving averages, RSI at 70, a bullish MACD crossover, and rising on-balance volume — pointing to strong near-term buying pressure. Momentum breakdown | RSI stays above 50 and price remains above the 200-day moving average for the next 2 quarters, sustaining the breakout structure. | →Stable |
| CounterRSI at 70 is already in overbought territory; a pullback from here would not be unusual, and if the breakout fails, technical support levels below current prices are sparse. | ||
With 26.6% headroom to the analyst price target at a roughly 3.8-to-1 favorable risk/reward ratio and institutions accumulating the stock, the setup offers meaningful upside for a speculative position if the clinical pipeline advances.
→StableSentiment breakdown
- Expectation
- Price converges toward the $18.27 analyst target over 12 months driven by positive clinical data from one or both programs.
CounterAnalyst coverage is light, which dampens signal reliability; if the latest large earnings miss reflects a change in the development trajectory, the target may be revised downward before price has a chance to reach it.
The business is burning cash with no revenue-generating operations, negative free cash flow, and no established competitive moat, leaving the quality profile well below the minimum threshold for a position addition at a score of roughly 1.6 out of 10.
→StableQuality breakdown
- Expectation
- Operating free cash flow turns positive for 2 consecutive quarters as the company moves toward a more capital-efficient clinical model.
CounterEarly-stage biotechnology companies by definition burn cash ahead of clinical milestones; the low financial-quality score reflects the stage of development rather than permanent impairment, and a positive clinical read-out from either program could transform the profile rapidly.
The company's entire value rests on two Phase 1 clinical programs — ERAS-0015 and ERAS-4001 — leaving the investment exposed to binary read-out risk with no diversification from commercial products or late-stage assets.
→StableBear case
- Expectation
- At least one of the two Phase 1 programs advances to Phase 2 within 18 months, validating the clinical development path.
CounterPipeline concentration is inherent to early-stage biotech; the 26.6% analyst-target upside suggests the market is already pricing in clinical risk, and institutional accumulation signals confidence in the probability of advancement.
The stock is in a confirmed breakout — golden cross in place, trading above all major moving averages, RSI at 70, a bullish MACD crossover, and rising on-balance volume — pointing to strong near-term buying pressure.
→StableMomentum breakdown
- Expectation
- RSI stays above 50 and price remains above the 200-day moving average for the next 2 quarters, sustaining the breakout structure.
CounterRSI at 70 is already in overbought territory; a pullback from here would not be unusual, and if the breakout fails, technical support levels below current prices are sparse.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Erasca is a cash-burning early-stage biotechnology company with all value concentrated in two Phase 1 clinical programs and a quality profile well below the minimum acceptable floor; the stock has broken out technically — above all key moving averages with a golden cross, RSI at 70, and rising institutional interest — and offers 26.6% headroom to the analyst target at a roughly 3.8-to-1 favorable risk/reward, but the absence of commercial operations, negative free cash flow, and a large recent earnings miss mean quality risk dominates the setup.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.1 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 1.9 |
- ▸Overbought (RSI 78)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.0 |
| Price target | 6.6 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (10.0) — signal dampened
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
2.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 1.1 |
| growth rank | 5.0 |
Technical
2.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.6 |
| support resistance | 0.1 |
| 52w position | 5.5 |
Risk (lower is worse)
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.3 |
| days to cover | 4.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 9.0 |
| debt equity | 9.5 |
- ▸High IV: 110%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.0>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:38d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.2=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.21
Upside
-3.1%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Insider at 7.3 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-0.2=NEGATIVE.
The strongest dimensions are Insider at 7.3, Momentum at 7.0, and Sentiment at 6.3; the weakest are Quality at 1.6, Technical at 2.1, and Catalyst at 2.5. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.21 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Minimum Floor
Trip ifOperating free cash flow rises above $0 for 2 consecutive quarters.
- P2Clinical Pipeline Concentration
Trip ifAt least 2 additional pipeline programs advance to Phase 2 or beyond, reducing single-program concentration.
- P3Technical Breakout Momentum
Trip ifRSI falls below 40 and price closes below the 200-day moving average for 10 consecutive sessions.
- P4Favorable Upside Asymmetry
Trip ifUpside to analyst target falls below 10% through price appreciation or a target reduction.